1. HCV Protease Inhibitors in Clinical Practice

2. Currently Approved HCV Agents: Telaprevir and Boceprevir

3. Patient Selection for HCV Triple Therapy

4. Telaprevir: Recommended Treatment Duration (Weeks)

5. Telaprevir + PEG-IFN-α-2a + RBV for HCV Genotype 1

6. Boceprevir: Recommended Treatment Duration (Weeks)

7. Boceprevir + PEG-IFN-α-2b + RBV for HCV Genotype 1

8. Select Predictors of SVR in Chronic HCV Genotype 1 Therapy

9. Selected Adverse Events

10. HCV Treatment-related Anemia

11. Preparing Patients for HCV Treatment

12. Abbreviations

13. Abbreviations (cont)

14. References

15. References (cont)

16. References (cont)